نتایج جستجو برای: pik3ca

تعداد نتایج: 2433  

2015
Ruza Arsenic Denise Treue Annika Lehmann Michael Hummel Manfred Dietel Carsten Denkert Jan Budczies

BACKGROUND Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to response to therapy. The aim of our study was to investigate the mutation status of PIK3CA gene and to evaluate the concordance between NGS and SGS for the most important hots...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Mattia Barbareschi Fiamma Buttitta Lara Felicioni Sabrina Cotrupi Fabio Barassi Maela Del Grammastro Antonella Ferro Paolo Dalla Palma Enzo Galligioni Antonio Marchetti

PURPOSE In breast cancer, the PIK3CA gene is frequently mutated at "hotspots" in exons 9 and 20, corresponding to the helical and kinase domains, respectively. We decided to investigate the association of PIK3CA mutations with pathologic features and clinical outcome in a large series of patients with breast cancer. EXPERIMENTAL DESIGN Frozen samples from 163 consecutive patients were analyze...

Journal: :OncoTargets and therapy 2016
Qiong He Qi Xu Wei Wu Lei Chen Weijing Sun Jieer Ying

PURPOSE In metastatic or recurrent colorectal cancer (MRCRC), the concordance of Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation status between the primary tumors and metastases is still controversial. The purpose of this study was to evaluate the association between KRAS and PIK3CA mutational status ...

2012
Amaury G. Dumont Sarah N. Dumont Jonathan C. Trent

The phosphatidylinositol-3 kinase(PI3K) pathway regulates a number of cellular processes, including cell survival, cell growth, and cell cycle progression. Consequently, this pathway is commonly deregulated in cancer. In particular, mutations in the gene PIK3CA that encodes the p110α catalytic subunit of the PI3K enzymes result in cell proliferation and resistance to apoptosis in vitro and indu...

Journal: :PLoS ONE 2009
Shun Liang Nuo Yang Yue Pan Shan Deng Xiaojuan Lin Xiaojun Yang Dionyssios Katsaros Katherine F. Roby Thomas C. Hamilton Denise C. Connolly George Coukos Lin Zhang

BACKGROUND The Phosphatidylinositol 3'-kinase is a key regulator in various cancer-associated signal transduction pathways. Genetic alterations of its catalytic subunit alpha, PIK3CA, have been identified in ovarian cancer. Our in vivo data suggests that PIK3CA activation is one of the early genetic events in ovarian cancer. However, its role in malignant transformation of ovarian surface epith...

2012
C.B. Murat P.B.S. Braga M.A.H.Z. Fortes M.D. Bronstein M.L.C. Corrêa-Giannella R.R. Giorgi

The tumorigenesis of pituitary adenomas is poorly understood. Mutations of the PIK3CA proto-oncogene, which encodes the p110-α catalytic subunit of PI3K, have been reported in various types of human cancers regarding the role of the gene in cell proliferation and survival through activation of the PI3K/Akt signaling pathway. Only one Chinese study described somatic mutations and amplification o...

2010
Katarzyna Wojciechowska-Durczyńska Kinga Krawczyk-Rusiecka Anna Cyniak-Magierska Arkadiusz Zygmunt Elżbieta Gałecka Andrzej Lewiński

BACKGROUND Recent studies have shown that the phosphatidylinositol 3-kinase (PI3K) signaling pathway is important regulator of many cellular events, including apoptosis, proliferation and motility. PI3K pathway alterations (PIK3CA gene mutations and/or amplification) have been observed in various human tumours. In the majority of diagnosed cases, mutations are localized in one of the three "hot...

2010
Magdalena Cizkova Géraldine Cizeron-Clairac Sophie Vacher Aurélie Susini Catherine Andrieu Rosette Lidereau Ivan Bièche

BACKGROUND The PI3K/AKT pathway plays a pivotal role in breast cancer development and maintenance. PIK3CA, encoding the PI3K catalytic subunit, is the oncogene exhibiting a high frequency of gain-of-function mutations leading to PI3K/AKT pathway activation in breast cancer. PIK3CA mutations have been observed in 30% to 40% of ERα-positive breast tumors. However the physiopathological role of PI...

2015
James E. Korkola Eric A. Collisson Laura Heiser Chris Oates Nora Bayani Sleiman Itani Amanda Esch Wallace Thompson Obi L. Griffith Nicholas J. Wang Wen-Lin Kuo Brian Cooper Jessica Billig Safiyyah Ziyad Jenny L. Hung Lakshmi Jakkula Heidi Feiler Yiling Lu Gordon B. Mills Paul T. Spellman

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2 breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 HER2 breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combinations of l...

2015
Ling Deng Jie Chen Xiao Rong Zhong Ting Luo Yan Ping Wang Hui Fen Huang Li-Juan Yin Yan Qiu Hong Bu Qing Lv Hong Zheng

BACKGROUND Abnormal activation of PI3K/AKT/mTOR (PAM) pathway, caused by PIK3CA mutation, KRAS mutation, PTEN loss, or AKT1 mutation, is one of the most frequent signaling abnormalities in breast carcinoma. However, distribution and frequencies of mutations in PAM pathway are unclear in breast cancer patients from the mainland of China and the correlation between these mutations and breast canc...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید